Necla GÜNGÖRLER, Leyla SEYHAN, Zafer PEKKOLAY

Two cases of euglycemic diabetic ketoacidosis caused by dapagliflozin

Hyperglycemia (Glucose> 250 mg/dL), metabolic acidosis (pH

Keywords:

Dapagliflozin, euglycemic ketoacidosis, sodium-glucose co-transporter 2 (SGLT-2) inhibitors,

PDF

___

1.Saeedi P, Petersohn I, Salpea P, et al. Global andregional diabetes prevalence estimates for 2019 andprojections for 2030 and 2045: Results from theInternational Diabetes Federation Diabetes Atlas.Diabetes Res Clin Pract. 2019; 157:107843.
2.Nyenwe EA, Kitabchi AE. The evolution of diabeticketoacidosis: An update of its etiology, pathogenesisand management. Metabolism. 2016;65(4):507-21.
3.Dhatariya, K.K., Glaser, N.S., Codner, E. et al.Diabetic ketoacidosis. Nat Rev Dis Primers 6, 40 (2020). https://doi.org/10.1038/s41572-020-0165-1.
4. Plosker GL. Dapaglifozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289–312.
5.Sethi SM, Vohra M, Ali SA. Euglycemıc DıabetıcKetoacıdosıs (Edka) In A Patıent ReceıvıngDapaglıflozın. Acta Endocrinol (Buchar). 2021 Apr-Jun;17(2):266-9.
6.Rawla P, Vellipuram AR, Bandaru SS, Pradeep RJ.Euglycemic diabetic ketoacidosis: a diagnostic andtherapeutic dilemma. Endocrinol Diabetes MetabCase Rep. 2017;2017(1).
7.Danne T, Garg S, Peters AL, et al. InternationalConsensus on Risk Management of DiabeticKetoacidosis in Patients With Type 1 DiabetesTreated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019;42(6):1147-54.
8.Clar C, Gill JA, Court R, Waugh N. Systematicreview of SGLT2 receptor inhibitors in dual or tripletherapy in type 2 diabetes. BMJ Open. 2012 Oct18;2(5): e001007.
9.Liu J, Li L, Li S, Wang Y, Qin X, Deng K, Liu Y, Zou K,Sun X. Sodium-glucose co-transporter-2 inhibitorsand the risk of diabetic ketoacidosis in patients withtype 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020 Sep;22(9):1619-27.
10.Peters AL, Buschur EO, Buse JB, et al. EuglycemicDiabetic Ketoacidosis: A Potential Complication ofTreatment With Sodium-Glucose Cotransporter 2Inhibition. Diabetes Care 2015; 38:1687.
11.Palmer BF, Clegg DJ, Taylor SI, Weir MR. Diabeticketoacidosis, sodium glucose transporter-2inhibitors and the kidney. J Diabetes Complications2016; 30:1162.
12.Ueda P, Svanström H, Melbye M, et al. Sodiumglucose cotransporter 2 inhibitors and risk ofserious adverse events: nationwide register basedcohort study. BMJ 2018; 363: k4365.
13. Moioli A, Maresca B, Manzione A, et al. Metformin associated lactic acidosis (MALA): clinical profilingand management. J Nephrol. 2016;29(6):783-789.doi: 10.1007/s40620-016-0267-8.
14.Nasa P, Chaudhary S, Shrivastava PK, Singh A.Euglycemic diabetic ketoacidosis: A misseddiagnosis. World J Diabetes. 2021 May15;12(5):514-23.